After a median follow-up of @ months ( IQR @-@ ) in the cisplatin plus gemcitabine group and @ months ( @-@ ) in the paclitaxel plus gemcitabine group , the hazard ratio for progression-free survival was @ ( @ % CI @-@ ; pnon-inferiority < @ , psuperiority = @ , thus cisplatin plus gemcitabine was both non-inferior to and superior to paclitaxel plus gemcitabine .